文献速递消化系统肿瘤

lncRNA HULC通过下调miR-29促进肝细胞癌生长

[LncRNA HULC promots HCC growth by downregulating miR-29].
PubMed 文献 · Zhonghua Zhong Liu Za Zhi · 2019-01-01

该研究探讨lncRNA HULC通过下调miR-29促进肝细胞癌(HCC)生长的机制。方法包括RT-qPCR检测HCC组织与细胞中HULC和miR-29表达、双荧光素酶报告基因验证靶向关系、CCK-8与Ki-67检测增殖、裸鼠移植瘤观察肿瘤体积。结果显示HULC在HCC中高表达、miR-29低表达且负相关,HULC靶向抑制miR-29并上调SETDB1,miR-29模拟物抑制增殖与成瘤,结论为HULC通过下调miR-29促进HCC生长。

要点

  • HCC组织与细胞中HULC高表达、miR-29低表达,两者呈负相关。
  • 双荧光素酶实验证实HULC靶向抑制miR-29,并上调其靶基因SETDB1。
  • miR-29模拟物抑制HCC细胞增殖与裸鼠成瘤,抑制物可逆转该效应。

核心结论

  • lncRNA HULC通过分子吸附并下调miR-29表达促进HCC细胞增殖,是其参与促进HCC生长的可能新机制。

研究设计与样本

  • 基础实验研究:采用RT-qPCR检测HCC组织与细胞中HULC和miR-29表达并作相关性分析,转染HULC过表达质粒或siRNA后检测miR-29与SETDB1表达。
  • 通过生物信息学预测HULC序列上的miR-29结合位点,构建报告基因质粒,与miR-29模拟物或抑制物共转染HCC细胞行双荧光素酶报告基因实验。
  • 以CCK-8法检测miR-29对HULC促HCC细胞增殖的影响,RT-qPCR检测Ki-67表达。
  • 建立Hep3B细胞裸鼠移植瘤模型,瘤内注射miR-29模拟物、抑制物或阴性对照,观察肿瘤体积,免疫组化检测肿瘤组织Ki-67蛋白。

主要发现

  • HCC组织和HCC细胞中HULC表达显著上调而miR-29显著下调(P<0.01)。
  • HULC与miR-29在HCC组织中呈负相关(r=-0.754,P<0.01),在HCC细胞中亦呈负相关(r=-0.865,P<0.05)。
  • 过表达HULC的Huh7细胞miR-29表达降低、SETDB1 mRNA升高(P<0.01);敲低HULC的Hep3B细胞miR-29升高、SETDB1 mRNA降低(P<0.01)。
  • 双荧光素酶实验显示miR-29模拟物抑制psi-HULC-WT转染Hep3B细胞的荧光素酶活性,对突变质粒无影响,miR-29抑制物可拮抗该抑制作用(P<0.01)。
  • 处理24、48、72 h后HULC过表达组Huh7细胞增殖率分别为(43.87±3.82)%、(83.45±7.46)%、(123.34±8.67)%,高于对照组(13.45±1.77)%、(23.54±1.37)%、(38.21±2.09)%(P<0.05)。

关键数值与推荐

  • 处理48和72 h后,miR-29模拟物转染Huh7细胞增殖率为(57.10±1.94)%和(73.76±3.46)%,低于对照组(83.45±7.46)%和(123.34±8.67)%(P<0.05)。
  • 处理48和72 h后,miR-29模拟物+miR-29抑制物组Huh7细胞增殖率为(76.45±3.24)%和(89.37±4.37)%,高于对照组(57.10±1.94)%和(73.76±3.46)%(P<0.05)。
  • 转染48 h,miR-29模拟物组Huh7细胞Ki-67 mRNA表达受抑制(P<0.01),miR-29抑制物组Ki-67 mRNA表达升高(P<0.01)。
  • 对照组、miR-29模拟物组、miR-29模拟物+miR-29抑制物组裸鼠移植瘤体积分别为(504.0±19.6) mm³、(310.0±24.3) mm³、(483.7±21.2) mm³。
  • 上述三组肿瘤组织Ki-67蛋白吸光度值分别为0.65±0.08、0.36±0.07、0.56±0.06,miR-29模拟物组降低(P<0.01),联合抑制物组升高(P<0.01)。

临床怎么用

  • 该研究为HCC中HULC/miR-29/SETDB1轴的机制探索,提示HULC高表达与miR-29低表达可能参与HCC增殖调控。
  • miR-29模拟物在细胞与裸鼠模型中显示抑制HCC增殖与成瘤的作用,为后续转化研究提供实验依据。

局限性

  • 研究为细胞与裸鼠移植瘤水平的临床前实验,HCC组织与细胞样本量未在摘要中报告。
  • HULC、miR-29及SETDB1作为HCC诊断、预后或治疗靶点的临床价值尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the effects of lncRNA HULC on hepatocellular carcinoma (HCC) growth by down-regulating miR-29. Methods: The expression levels of HULC and miR-29 in HCC tissues and cells were detected by real-time quantitative PCR (RT-qPCR), and the correlation analysis was performed. After HCC cells were transfected with HULC overexpressed plasmid or siRNA, the expressions of miR-29 and its target gene SETDB1 were determinate by RT-qPCR. According to the bioinformatic prediction of the miR-29 binding site in the HULC sequence, the report gene plasmids were constructed. The HCC cells were co-transfected with miR-29 mimics or miR-29 inhibitor, and the HULC targeted regulation of miR-29 was verified by dual luciferase reporter assay. The effect of miR-29 on the HULC-mediated proliferation in HCC cells was detected by cell count kit 8 (CCK-8) experiment. Expression of tumor proliferation antigen Ki-67 was detected by RT-qPCR.The Hep3B cells were inoculated in mice and miR-29 mimics and miR-29 negative control (NC) further injected into the lesions. The tumor volume was observed, and the expressions of tumor proliferation antigen ki-67 in tumor tissues were detected by immunohistochemical staining. Results: The expression of HULC was significantly up-regulated while the expression of miR-29 was significantly down-regulated in HCC tissues and cells (P<0.01). The level of HULC was negatively correlated with miR-29 in tumor tissues (r=-0.754, P<0.01) and HCC cells (r=-0.865, P<0.05). The in vitro experiments showed that, compared with the blank control group, the expression of miR-29 in HULC overexpressed Huh7 cells was significantly reduced, while the mRNA level of miR-29 target gene SETDB1 was increased (P<0.01). The expression of miR-29 was significantly increased in HULC deleted Hep3B cells, while the mRNA expression of SETDB1 was decreased (P<0.01). Double luciferase reporter gene assay showed that miR-29 mimics significantly inhibited the luciferase activity of Hep3B cells transfected with HULC wide type (psi-HULC-WT) plasmid but had no effect on Hep3B cells transfected with mutant plasmid (psi-HULC-Mut). However, the miR-29 inhibitor antagonized the inhibitory effect of miR-29 mimics on luciferase activity of psi-HULC-WT (P<0.01). Cell proliferation experiments showed that, compared with the control group, the proliferation ability of miR-29 mimics overexpressed Huh7 cells was significantly reduced.After 24, 48 and 72 hours of treatment, the proliferation rates of Huh7 cells in the HULC overexpressed group were (43.87±3.82)%, (83.45±7.46)% and (123.34±8.67)%, respectively, significantly higher than (13.45±1.77)%, (23.54±1.37)% and (38.21±2.09)% of control group (P<0.05). After treatment for 48 and 72 hours, the proliferation rates of miR-29 mimics transfected Huh7 cells were (57.10±1.94)% and (73.76±3.46)%, respectively, significantly lower than (83.45±7.46)% and (123.34±8.67)% of control group (P<0.05). After treatment for 48 and 72 hours, the proliferation rates of Huh7 cells transfected with miR-29 mimics and miR-29 inhibitor group were (76.45±3.24)% and (89.37±4.37)%, respectively, significant higher than (57.10%±1.94)% and (73.76±3.46)% of the control group (P<0.05). After 48 h transfection, the expression of Ki-67 in Huh7 transfected with miR-29 mimics was significantly inhibited compared with the control group (P<0.01). However, the expression of Ki-67 mRNA was increased in Huh7 cells transfected with miR-29 inhibitor (P<0.01). The results of in vivo experiments showed that the tumor volumes of the control group, miR-29 mimics group and miR-29 mimics + miR-29 inhibitors group were (504.0±19.6) mm(3), (310.0±24.3) mm(3) and (483.7±21.2) mm(3), respectively. Injection of miR-29 mimics reduced while miR-29 inhibitor promoted tumorigenesis ability of Huh7 in nude mice (P<0.01). The immunohistochemical staining showed that the average optical density values of Ki-67 protein in tumor tissues of the control group, miR-29 mimics group and miR-29 analogue+ miR-29 inhibitor group were 0.65±0.08, 0.36±0.07 and 0.56±0.06, respectively. The expression level of Ki-67 protein in miR-29 mimics group was significantly reduced (P<0.01) while increased in the miR-29 mimics+ miR-29 inhibitor group (P<0.01). Conclusion: LncRNA HULC promotes HCC growth by down-regulating miR-29. 目的: 探讨长链非编码RNA(lncRNA)HULC通过下调微小RNA-29(miR-29)的表达促进肝细胞癌(HCC)细胞增殖的作用及分子机制。 方法: 运用实时荧光定量PCR法检测HCC组织和细胞中HULC和miR-29的表达水平,并进行相关性分析。HCC细胞转染HULC过表达质粒或以小干扰RNA(siRNA)敲低HULC的表达,以实时荧光定量PCR检测miR-29和靶基因SET结构域分支1(SETDB1)的表达水平。通过生物信息学预测HULC序列上存在的miR-29结合位点,构建报告基因质粒与miR-29模拟物、miR-29抑制物共转染HCC细胞,通过双荧光素酶报告基因实验验证HULC靶向调控miR-29的分子机制。以细胞计数盒8(CCK-8)法检测miR-29对HULC的促HCC细胞增殖作用的影响。以实时荧光定量PCR法检测Ki-67的表达。建立Hep3B细胞移植瘤模型,瘤内注射miR-29模拟物、miR-29抑制物、miR-29阴性对照,观察肿瘤体积。采用免疫组化法检测小鼠肿瘤组织中肿瘤增殖抗原Ki-67的表达。 结果: 与癌旁组织和正常肝细胞比较,HULC在HCC组织和HCC细胞中均呈高表达(P<0.01),而miR-29均呈低表达(P<0.01),HULC和miR-29在HCC组织(r=-0.754,P<0.01)和HCC细胞(r=-0.865,P<0.05)中的表达均呈负相关。与空白对照组比较,过表达HULC组Huh7细胞中miR-29表达明显降低,而miR-29靶基因SETDB1 mRNA的表达升高(P<0.01),si-HULC组Hep3B细胞中miR-29表达明显升高,而miR-29靶基因SETDB1 mRNA的表达降低(P<0.01)。miR-29模拟物可显著抑制转染psi-HULC-WT质粒组但不能抑制转染突变(psi-HULC-Mut)组Hep3B细胞的荧光素酶活性,而miR-29抑制物可拮抗miR-29模拟物对psi-HULC-WT荧光素酶活性的抑制作用(P<0.01)。与对照组比较,miR-29模拟物组Huh7细胞的增殖能力明显减弱。处理24、48和72 h后,HULC过表达组Huh7细胞的增殖率分别为(43.87±3.82)%、(83.45±7.46)%和(123.34±8.67)%,与对照组[分别为(13.45±1.77)%、(23.54±1.37)%和(38.21±2.09)%]比较,差异有统计学意义(P<0.05)。处理48和72 h后,转染miR-29模拟物组Huh7细胞的增殖率分别为(57.10±1.94)%和(73.76±3.46)%,与对照组[分别为(83.45±7.46)%和(123.34±8.67)%]比较,差异有统计学意义(P<0.05)。处理48和72 h后,转染miR-29模拟物+miR-29抑制物组Huh7细胞的增殖率分别为(76.45±3.24)%和(89.37±4.37)%,与对照组[分别为(57.10±1.94)%和(73.76±3.46)%]比较,差异有统计学意义(P<0.05)。与对照组比较,转染48 h,转染miR-29模拟物Huh7细胞中Ki-67 mRNA的表达明显受到抑制(P<0.01)。转染miR-29抑制物Huh7细胞中Ki-67 mRNA的表达升高(P<0.01)。对照组、miR-29模拟物组和miR-29模拟物+miR-29抑制物组裸鼠移植瘤的肿瘤体积分别为(504.0±19.6)mm(3)、(310.0±24.3)mm(3)和(483.7±21.2)mm(3)。与对照组比较,miR-29模拟物组的裸鼠成瘤能力明显降低(P<0.01)。与miR-29模拟物组比较,miR-29模拟物+miR-29抑制物组裸鼠成瘤能力增强(P<0.01)。对照组、miR-29模拟物组、miR-29模拟物+miR-29抑制物组荷瘤鼠肿瘤组织中Ki-67蛋白的吸光度值分别为0.65±0.08、0.36±0.07、0.56±0.06。与对照组比较,miR-29模拟物组Ki-67蛋白表达量明显降低(P<0.01)。与miR-29模拟物组比较,miR-29模拟物+miR-29抑制物组Ki-67蛋白表达量升高(P<0.01)。 结论: lncRNA HULC通过分子吸附miR-29、并下调miR-29的表达促进HCC细胞增殖。HULC下调miR-29表达可能是其参与促进HCC生长的新机制。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhu LR, Feng JL, Liu XJ, et al. [LncRNA HULC promots HCC growth by downregulating miR-29]. Zhonghua Zhong Liu Za Zhi. 2019. PMID: 31550855. doi:10.3760/cma.j.issn.0253-3766.2019.09.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。